Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly lower. Moderna (MRNA) was the best-performing stock in the S&P 500 as Barron's called it "too cheap" and named the biotech firm ...

Moderna said it is suing Pfizer and its German partner BioNTech for patent infringement linked to the development of the first Covid-19 vaccines. The US biotech company is alleging that mRNA ...

Thinking about adding a biotech company to your portfolio? Here's what to know before buying Moderna stock. Many, or all, of the products featured on this page are from our advertising partners ...